Agilent Announces the Availability of Objective Decision Support for Pathologists Reviewing Breast Cancer Cases
October 08 2020 - 10:32AM
Business Wire
An exciting development for digital pathology
Agilent Technologies Inc. (NYSE: A) today announced the
expansion of Visiopharm’s validated image analysis algorithm to
incorporate HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD
marked and recently released for sale in Europe. This development
enables pathologists to use the Visiopharm HER2 APP for objective
decision support in the assessment of HercepTest™ mAb pharmDx
stained slides, saving valuable time for both pathologists and
patients.
The HercepTest™ mAb pharmDx assay is intended for breast cancer
patients where Herceptin® treatment is being considered.
HercepTest™ mAb pharmDx (Dako Omnis) includes a rabbit monoclonal
antibody that provides robust and reproducible staining of the
cancer biomarker, Human Epidermal Growth Factor Receptor 2 (HER2)
in breast cancer tissue. If HER2 is over-expressed, the patient may
be a candidate for Herceptin® treatment, which targets HER2 in the
cancer cell.
Visiopharm’s HER2 APP uses automated image analysis to
reproducibly assess and score HER2 staining in brightfield digital
images of breast cancer tissue sections. The APP provides objective
decision support to pathologists, who would traditionally only
visually review slides under a microscope. This decision support
reduces the number of inconclusive readings and therefore saves the
pathologist time, and helps to provide a faster, more accurate
diagnosis for the patient.
Dirk Vossen, Chief Diagnostics Officer of Visiopharm commented,
“The HER2 APP delivers objective, reproducible diagnostic decision
support that enables pathologists to quickly and accurately review
staining results. We are delighted that the algorithm is now
validated for HercepTest™ mAb pharmDx for Dako Omnis.”
Furthermore, the addition of HercepTest™ mAb pharmDx assay to
the Dako Omnis menu means that pathology labs can further benefit
from patient case management with Dako Omnis, which helps them
improve case delivery times and provide consistent, precise results
for patients.
“Together, the HercepTest™ mAb pharmDx for Dako Omnis and
Visiopharm’s HER2 APP represents an exciting step forward in our
shared commitment towards improving end-to-end standardization in
tissue diagnostics, enabling our customers to quickly and
efficiently generate accurate diagnoses,” remarked Simon
Østergaard, Agilent vice president and general manager of the
company’s pathology group.
For in vitro diagnostic use in Europe.
HercepTest™ mAb pharmDx (Dako Omnis) (Code GE001): The licensed
antibody is created by Epitomics Inc. (an Abcam company), using
Abcam’s proprietary rabbit monoclonal antibody technology covered
under Patent No’s 5,675,063 and 7,402,409.
HercepTest™ and Herceptin® are trademarks owned by Genentech,
Inc.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201008005702/en/
Media Contact: Catherine Kaye Agilent Technologies
+447775 410632 catherine.kaye@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024